ACCESS Newswire

China XLX Fertiliser

9.8.2021 06:43:16 CEST | ACCESS Newswire | Press release

Share
China XLX Announces 2021 Interim Results Strong and Solid Recovery with NP Surging by 259%

2021 Interim Results Highlights:

  • Achieved revenue of approximately RMB 7,573 million, rising by 53% Y-O-Y.
  • Revenue derived from the sales of urea increased by 32% Y-O-Y to approximately RMB2,074 million. Gross profit margin of urea increased to approximately 35.4% from approximately 26.8% last year.
  • The unaudited total comprehensive income attributable to the owners of the parent increased significantly by 259% to approximately RMB646 million for 1H2021. Earnings per share reached 55.1 RMB cents in 1H2021.

HONG KONG / ACCESSWIRE / August 9, 2021 / China XLX Fertiliser Ltd. ("China XLX" or the "Company", together with its subsidiaries collectively known as the "Group") (HKSE:01866.HK) announced the interim results o for the six months ended 30 June 2021 (the "Period"). The Group recorded a revenue of approximately RMB7,573 million, increased by 53% from the same period last year. Gross profit increased sharply by 99.4% to approximately RMB2,118 million. Profit for the period surged by 237% to approximately RMB 889 million from last year. The comprehensive income attributable to owners of the parent company jumped by 259% to approximately RMB646 million, as compared with the same time last year.

In the first half of 2021, the recovery of the domestic fertilisers and chemical products market has accelerated. With the Group's third production base in Jiangxi Jiujiang successfully commissioned in February 2021, total production capacity reached new height, further solidifying geographical coverage, forming Central, Northwest and Southeast three strategic production bases in the PRC.

With the Jiujiang production base put into production, the market share of the Group has increased and its cost advantage has been further enhanced. Additionally, the rising global food price and increasing demand further boosted the sales of key products of the Group, contributing to satisfying results for 1H2021. Revenue derived from the sales of urea increased by 32% to approximately RMB2,074 million. The leap was mainly due to the increase in sales volume and the average selling price of urea products of the Group by approximately 8% and 23% Y-O-Y, respectively. Gross profit margin of urea of the Group increased to approximately 35.4% for 1H2021 from approximately 26.8% for 1H2020.

Strong results have also been recorded in the businesses of compound fertilisers and methanol. Revenue derived from the sales of compound fertilisers increased by 13% to approximately RMB1,981 million for 1H2021, mainly due to the increase in sales volume and average selling price of compound fertilisers by approximately 5% and 8% respectively. Revenue derived from the sales of methanol was up by 355% to approximately RMB733 million for 1H2021. The increased sales of methanol were a result of the increase in average selling price and sales volume of methanol of the Group by 57% and 190% YoY respectively. The increased sales volume was mainly contributed by the additional production capacity of the third production base in Jiujiang. Due to the rebound in international energy prices which in turn boosted the average selling price of methanol, gross profit margin of methanol of the Group rose by approximately 22 percentage points to approximately 19.7% for 1H2021.

Revenue derived from the sales of Dimethyl Ether (DME) rose by 79% to approximately RMB618 million for 1H2021. Revenue derived from the sales of melamine increased largely by 69% to approximately RMB535 million for 1H2021. Revenue derived from the sales of furfuryl alcohol products was up by 48% to approximately RMB335 million for 1H2021. The revenue from the sales of urea solution for vehicle reached approximately RMB236 million for 1H2021, due to product structure adjustment.

Looking ahead, Mr. Liu Xingxu, Chairman of China XLX, said that with the introduction of the new agricultural reform policies and the "dual-carbon" policies, the acceleration of elimination of the backward production capacity and emphasis on the high-quality and efficient green development of the agriculture industry would be beneficial to the development of industry leaders. The Group adheres to the strategy of green, low carbon and sustainable development in terms of production, R&D or product innovation, which will provide favourable conditions for consolidating the main fertilisers industry. In addition, the chemical product market is affected by rising international energy prices, strong downstream demand, and the business cycle of chemical product prices will continue at a high level. Each of the Group's chemical product can meet the various needs of its downstream users. On the basis of consolidating the competitive advantages of our existing chemical products, the Group would be committed to extending the development of the industrial chain. As new products continue to be put into production, it will definitely further enhance the Group's profitability and market competitiveness.

Since the Jiujiang production base has been put into production, the market share of the Group has increased and its cost advantage has been further enhanced. The Group will leverage its three major production bases to strengthen its competitive advantage of "low-cost and differentiation" and widen its business horizon. Being committed to leading the industry as "Pioneer of High-Efficiency Fertilisers in China" to lead the industry with higher standard and support the industry's continuous exploration in high efficiency fertiliser and scientific agriculture, the Group strives to reward farmers and serve the community with higher standards, and to make higher contribution to China agriculture.

~END~

About China XLX Fertiliser Ltd.

China XLX Fertiliser Ltd. is one of the largest and most cost-efficient coal-based urea producers in China. The Group is principally engaged in developing, manufacturing, and selling of related differentiated products such as urea, compound fertiliser, methanol, dimethyl ether, melamine, furfuryl alcohol, furfural, 2-methylfuran and pharmaceutical intermediates. Adhering to the competitive strategy of combination of "comprehensive cost control and product differentiation", the Group aims at further development of the fertiliser industry as a whole. Boasting resources of its Henan, Xinjiang, Jiujiang bases, the Group strives to expand its business into various upstream product lines including new energy, new chemical materials, and coal chemicals. The Group is committed to becoming the most respected enterprise in the chemical fertilisers industry. The Company's shares are traded on the main board of the Stock Exchange of Hong Kong Limited (stock code: 01866.HK).

Investor and Media Enquiries

China XLX Fertiliser Ltd.
GUI, Lin
Tel: 86-135 6942 3415
Email: lin.gui@chinaxlx.com.hk

PRChina Limited
Joanne Liu/ Jack Liu/ Rachel Xia
Tel: 852-2522 1368 / 852-2522 1838
Email: jjyliu@prchina.com.hk
zyliu@prchina.com.hk
rxia@prchina.com.hk

SOURCE: China XLX Fertiliser



View source version on accesswire.com:
https://www.accesswire.com/658898/China-XLX-Announces-2021-Interim-Results-Strong-and-Solid-Recovery-with-NP-Surging-by-259

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Dr. Christoph Themel as Partner3.2.2026 11:30:00 CET | Press release

TORONTO, ON AND LONDON, UK / ACCESS Newswire / February 3, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Dr. Christoph Themel as a Partner in the firm's Life Sciences and Healthcare Practice. Based in London, Dr. Themel advises boards, investors, and senior leadership teams on executive and non-executive appointments, leadership assessments, and succession planning across the pharmaceutical, biotechnology, and animal health sectors. Dr. Christoph Themel joins Caldwell as partner in the firm's Life Sciences and Healthcare Practice With more than 20 years of experience in executive search and leadership advisory, Dr. Themel is a trusted advisor to big and mid-sized pharmaceutical companies, family-owned enterprises, private equity firms, and portfolio company leadership teams across Europe, the United States, and Asia Pacific. He is particularly known for his ability to partner closely with shareholders and management teams on C-sui

AI Rises on the Finance Leadership Agenda as Cost Control Dominates 2026, New Survey Reveals3.2.2026 10:00:00 CET | Press release

MANCHESTER, UK / ACCESS Newswire / February 3, 2026 / AccessPay, the leading bank integration provider, today announced the release of its Finance Trends 2026 report, presenting the findings of its annual survey of finance leaders. In this fourth year of the report, AccessPay reveals marked sectoral differences between finance teams in financial services firms and those in corporates with regards to their priorities and attitudes to technology adoption. Key findings from the report include: 1. Finance leaders are prioritising finance efficiency and cost control Finance teams across all sectors are placing renewed emphasis on efficiency and cost control in 2026. 47% of general corporates cited this as a priority, a goal shared by 46% of financial services firms. Although cost control is a perennial concern in financial management, sluggish economic growth, rising costs, and geopolitical turmoil have brought it to the fore. Finance leaders are being pushed to do more with less, which als

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades2.2.2026 15:00:00 CET | Press release

Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications. This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup. With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgi

Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor2.2.2026 13:30:00 CET | Press release

This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025. MIAMI, FL / ACCESS Newswire / February 2, 2026 / Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy. Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationw

Formerra to Supply Foster Medical Compounds in Europe29.1.2026 15:00:00 CET | Press release

Expanded agreement infuses Formerra's European healthcare polymer portfolio with life-saving Foster® compounds. PUTNAM, CT AND ROMEOVILLE, IL / ACCESS Newswire / January 29, 2026 / Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions. Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye